Taiho Oncology and Astex Pharmaceuticals Present Overall Sur

Patients in Phase 3 ASCERTAIN study with biallelic TP53 mutations achieved median overall survival (mOS) of 13 months; mOS in the overall study po...

Related Keywords

Oakville , Ontario , Canada , United States , New Jersey , United Kingdom , France , Switzerland , Canadian , French , American , British , Michael Savona , Garcia Manerog Myelodysplastic , Samer Zeidan , Judy Kay Moore , Martin Buckland , Tim Whitten , Guillermo Garcia Manero , American Cancer Society Web , Cancer Research United Kingdom Web , Taiho Pharmaceutical Co Ltd , American Society Of Hematology , Taiho Pharma Canada Inc , Taiho Oncology Inc , International Prognostic Scoring System , Otsuka Pharmaceutical Co Ltd , Otsuka Holdings Co Ltd , National Comprehensive Cancer Network , Cancer Biology At Vanderbilt University , Astex Pharmaceuticals , Early Therapy Program , Health Canada , Astex Pharmaceuticals Inc , Hematologic Malignancies Research , Taiho Oncology , American Society , Annual Meeting , National Comprehensive Cancer , Clinical Practice Guidelines , Myelodysplastic Syndromes , Confidence Interval , Internal Medicine , Cancer Biology , Vanderbilt University , Data Presentations , Taiho Pharma Canada , Full Prescribing , Chronic Myelomonocytic Leukemia , Cedazuridine Fixed Dose Combination , About Taiho Oncology , Practice Guidelines , Accessed November , Hematol Malig ,